3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
6
Breast Neoplasms
3
Pancreatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pain
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
297
Rituximab
272
Etoposide
149
Filgrastim
142
fludarabine phosphate
120
Cytarabine
109
Vincristine
107
Melphalan
102
Radiotherapy
101
Doxorubicin
97
Peripheral Blood Stem Cell Transplantation
93
Methotrexate
91
fludarabine
86
Prednisone
86
Busulfan
86
Tacrolimus
66
Mycophenolic Acid
62
Granulocyte Colony-Stimulating Factor
60
Antilymphocyte Serum
58
Dexamethasone
57
Whole-Body Irradiation
55
Carmustine
54
Bortezomib
45
Cyclosporine
44
Lenalidomide
41
Methylprednisolone
40
sargramostim
39
Bendamustine Hydrochloride
37
ibritumomab tiuxetan
34
Ifosfamide
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma
×
Genistein
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts